Diversity of intestinal microbiota among Thai IBS-D patients and impact of probiotic as an adjuvant therapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20191211006

Enrollment

Registered

2019-12-11

Start date

2018-10-09

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gut microbiota Irritable bowel syndrome with diarrhea gut microbiota irritable bowel syndrome with diarrhea

Interventions

Probiotic rich in Bifidobacterium and Lactobacillus

Experimental Drug

Infloran(probiotic)

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Diagnosed IBS-D according to ROME IV criteria

Exclusion criteria

Exclusion criteria: Received probiotic or antibiotic within 3 months

Design outcomes

Primary

Measure	Time frame
Amount of gut microbiota at baseline 16s rRNA sequencing gene	—

Secondary

Measure	Time frame
IBS severity at baseline, 4 wks and 8 wks after probiotic IBS-SSS scores ,Quality of life at baseline, 4 wks and 8 wks after probiotic SF-36 scores ,Amount of gut microbiota 8 wks after probiotic 16s rRNA sequencing gene	—

Countries

Thailand

Contacts

Public ContactSawangpong Jandee

Prince of Songkla University

tekikung@gmail.com66896461605

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Diversity of intestinal microbiota among Thai IBS&#45;D patients and impact of probiotic as an adjuvant therapy